Black Education and Treatment of Hypertension (BEAT HTN)

Summary

Clinical trials have yet to test the adequacy of HTN control in African Americans (AA) when both control and intervention groups are given free antihypertensive medications and are involved in usual versus intensive intervention strategies. Because of this, it has not yet been determined whether the method of prescribing antihypertensive medications according to JNC 7 guidelines is more, less, or equally as effective as prescribing antihypertensive medications and providing intensive behavioral and clinical interventions. Knowledge in this area of HTN treatment should better able medical and health practitioners to help their AA subjects control HTN. The BEAT Hypertension Clinic will evaluate this method of HTN control by proposing a program that will evaluate the difference in HTN control among subjects receiving usual care and free medications and subjects also receiving free medications, but additionally being treated in a clinic that operates in a more intensive manner in relationship to patient behavior modification, patient-clinician interactions, and physical and social environments. At the conclusion of the study, the BEAT Hypertension Clinic investigators will report findings and help to answer the question of whether medication alone or medication combined with intensive behavioral and clinical treatment is more effective in HTN control in the AA population.

Conditions

• Hypertension

Interventions

DRUG

Hydrochlorothiazide

Hydrochlorothiazide 25 mg tablets

DRUG

Lisinopril

Lisinopril 5mg Tablet, 10 mg tablet, 20 mg tablet

DRUG

Lisinopril and Hydrochlorothiazide

L 10 mg and H 12.5 mg tablets, L 20 mg and H 12.5 mg tablets, L 20 mg and H 25 mg tablets

DRUG

Nifedipine XL

30 mg extended release tablets, 60 mg extended release tablets

DRUG

Metoprolol tartrate

50 mg tablets \& 100 mg tablets

DRUG

Atenolol

50 mg tablet

DRUG

Valsartan

80 mg tablets \& 160 mg tablet

DRUG

Doxazosin

4 mg tablets

DRUG

Clonidine

0.2 mg tablets

DRUG

Hydralazine

50 mg tablets

DRUG

Metoprolol succinate

50 mg tablet \& 100 mg tablet

DRUG

Amlodipine

5 mg tablets \& 10 mg tablets

Sponsors & Collaborators

• Creighton University

  lead OTHER

Principal Investigators

• Syed Mohiuddin, MD · Creighton University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

25 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2005-08-31

Primary Completion

2009-08-31

Completion

2009-11-30

Countries

• United States

Study Locations